不同剂型利福平对比治疗肺结核疗效和安全性的Meta分析

发布时间：2018-02-08 20:25

本文关键词： 利福平注射液口服利福平肺结核 Meta分析疗效安全性　出处：《中国药房》2015年15期 　论文类型：期刊论文

【摘要】：目的:系统评价不同剂型利福平对比治疗肺结核的疗效和安全性,以为临床治疗提供循证参考。方法:计算机检索Ovid-medline、Pub Med、EMBase、Cochrane图书馆、相关期刊论文、中文科技期刊数据库、万方数据库和相关网站,收集利福平注射液(试验组)对比利福平胶囊/片剂(对照组)治疗肺结核的随机对照试验(RCT),提取资料并进行质量评价后,采用Rev Man 5.2统计软件进行Meta分析。结果:共纳入18项RCT,合计1 646例患者。Meta分析结果显示,试验组患者痰菌转阴率[初治RR=1.20,95%CI(1.12,1.27),P0.000;复治RR=1.23,95%CI(1.04,1.46),P=0.02;继发RR=1.23,95%CI(1.12,1.34),P0.000]和病灶吸收率[初治RR=1.18,95%CI(1.10,1.26),P0.000;复治RR=1.37,95%CI(1.03,1.82),P=0.03;继发RR=1.20,95%CI(1.11,1.31),P0.000]均显著优于对照组,两组比较差异均有统计学意义;两组患者肝功能异常发生率比较差异无统计学意义[RR=0.98,95%CI(0.78,1.23),P=0.86]。结论:利福平注射液治疗初治、复治、继发性肺结核的疗效显著优于口服剂型,安全性相当。由于纳入研究质量一般,该结论有待大样本、高质量的RCT进一步验证。
[Abstract]:Objective: To evaluate the efficacy and safety of different dosage of contrast of rifampicin in the treatment of pulmonary tuberculosis, in order to provide references for clinical evidence-based. Methods: We searched Ovid-medline, Pub Med, EMBase, Cochrane library, Chinese CNKI, Chinese journals database, Wanfang database and related website, Rifampicin Injection collection (test group) Rifampicin Capsules / tablet (control group) randomized controlled trials for treatment of pulmonary tuberculosis (RCT), and evaluate the quality of extracted data, using Rev Man 5.2 statistical software for Meta analysis. Results: 18 RCT were included, with a total of 1646 cases of.Meta analysis results showed that the test group the sputum negative conversion rate of early treatment of RR=1.20,95%CI (1.12,1.27), P0.000 RR=1.23,95%CI (1.04,1.46); retreatment, P=0.02; secondary RR=1.23,95%CI (1.12,1.34), P0.000] and lesions absorption rate [untreated RR=1.18,95%CI (1.10,1.26), P0.000 complex; Treatment of RR=1.37,95%CI (1.03,1.82), P=0.03 RR=1.20,95%CI (1.11,1.31); secondary, P0.000] were significantly better than the control group, the two groups there were statistically significant differences between the two groups of patients with abnormal liver function; there were no significant differences in [RR=0.98,95%CI (0.78,1.23), P =0.86]. conclusion: Rifampicin Injection for the initial treatment, relapse, treatment of secondary pulmonary tuberculosis superior oral dosage, safety. Due to the quality of the included studies, this conclusion needs large sample, high quality RCT was further validated.

【作者单位】：河南省胸科医院药剂科;
【基金】：国家科技支撑计划课题(No.2013BAI06B04)
【分类号】：R521

【参考文献】